Navigation Links
Rendell Administration Announces Health Research Grants From Tobacco Settlement Funds
Date:2/20/2009

HARRISBURG, Pa., Feb. 20 /PRNewswire-USNewswire/ -- Health Secretary Everette James today announced four health research grants totaling nearly $18 million will be awarded from Pennsylvania's share of the national tobacco settlement for 2008-09.

These competitive grants focus on specific research priorities established and reviewed annually by the statewide Health Research Advisory Committee, chaired by Secretary James. The priorities for 2008-09 are autism spectrum disorders (ASD) and antibiotic resistance. Each grant is required to establish a research training program for minority students and faculty in order to create a diverse applicant pool for high-level research positions.

"These grants will support research that seeks to find answers to some of Pennsylvania's most pressing health issues," said Secretary James. "This announcement also reaffirms Governor Rendell's commitment to use tobacco settlement dollars to improve public health and maintain Pennsylvania's internationally recognized leadership in clinical and health services research."

Antibiotic-resistant infections are a growing and serious public health problem, particularly in health care settings. While most bacterial infections can be effectively controlled using existing antibiotic drugs, there has been a significant increase in antibiotic drug resistance rates in health care institutions during the past 25 years. It has been estimated that more than 70 percent of the bacteria that cause health care infections have resistance to at least one or more antibiotic drugs. More than 27,000 hospital-acquired infections were reported in Pennsylvania in 2007. Patients that acquired a hospital infection stayed more than three times longer in the hospital and their admission was four times as expensive as any other hospital admission. Many of these infections are caused by bacteria resistant to most, if not all, currently available drugs. '/>"/>

SOURCE Pennsylvania Department of Health
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ISTA Pharmaceuticals New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
2. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
3. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
4. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
5. New AAHC Toolkit Available to Optimize Clinical Research Administration
6. New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
7. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
8. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
9. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
10. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
11. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...EN BURNIE, Md., Dec. 1 Sleep Solut...vice provider for home testing and evaluation of s...named Richard Hassett, M.D., as its chief executiv... Matria Healthcare, during its growth from a $250 ...lion industry leader in total population health, a...
(Date:12/1/2009)..., PISCATAWAY, N.J., Dec. 1 Siemen.../hearing) a leading global manufacturer of hearing...ip with Quota International,s Sound Beginnings pro...mber 2010. ,, As part of the renewed partnershi...chers for 100 free hearing instruments to both chi...
(Date:12/1/2009)..., CHENGDU, China, Dec. 1 /PRNewswire-Asia-Fi...E Amex: TPI ), a manufacturer and supplier of,mod... in Chengdu, China, today,announced that it has re...rug,Administration (SFDA) to produce Pediatric Fev...ube (SFDA approval number Z20093060) and Antibacte...
Breaking Medicine Technology:Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 2Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 3Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 2Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 3Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 3PAREXEL Experts to Present Leading Insights at Drug Information Association Annual Clinical Forum 59729 1PAREXEL Experts to Present Leading Insights at Drug Information Association Annual Clinical Forum 59729 2PAREXEL Experts to Present Leading Insights at Drug Information Association Annual Clinical Forum 59729 3PAREXEL Experts to Present Leading Insights at Drug Information Association Annual Clinical Forum 59729 4AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin 28AEZS 130 29 as First Oral Diagnostic Test for Growth Hormone Deficiency 14520 1AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin 28AEZS 130 29 as First Oral Diagnostic Test for Growth Hormone Deficiency 14520 2AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin 28AEZS 130 29 as First Oral Diagnostic Test for Growth Hormone Deficiency 14520 3PEER 1 Celebrates 10th Anniversary 59725 1PEER 1 Celebrates 10th Anniversary 59725 2PEER 1 Celebrates 10th Anniversary 59725 3
... Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) today...ampridine-SR in people with multiple sclerosis (MS...drew Goodman, M.D.,Director of the Multiple Scler...ted top-line results on walking ability, leg,stren...mpressions.,Dr. Goodman also presented a review of...
...onclinical (IND) In- Vitro,Studies for Promising A...SWIRE) -- Samaritan,Pharmaceuticals Inc. (AMEX:LIV...announce positive results were attained with its,l...spinol (SP-233),with well recognized in-vitro mod...mperfect predictors,of clinical responses, laborat...
Other Medicine Technology:Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro,Studies for Promising Alzheimer's Drug 2Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro,Studies for Promising Alzheimer's Drug 3
(Date:12/1/2009)..., SOUTHFIELD, Mich., Dec. 1 /PRNewswire-FirstCa...: FMR ) ("First Mercury" or the "Company") annou...Directors declared a quarterly cash dividend of $0...areholders of record at the close of business on D...ancial Corporation ,, First Mercury Financial ...
(Date:12/1/2009)...es H1N1 vaccination because pandemic,s course rema...ealthDay News) -- A U.S. health official said Tues... the wane nationally, but many experts agreed the ..., The flu is now widespread in 32 states -- down f...en, director of the U.S. Centers for Disease Contr...
(Date:12/1/2009)... , RESEARCH TRIANGLE PARK, N.C., Dec. 1 /PRNe...ated in 2001 and have expanded over the years serv.... The facility which was originally set up in an a...acy services, as part of the suite of services by ...dustry as a valuable offering. ,, The pharmacy ...
(Date:12/1/2009)..., WASHINGTON, Dec. 1 ... for International Development: ,, Chairman Ker...ttee. ,, I am honored to be nominated by Presid...States Agency for International Development, and I...y. ,, Secretary of State Clinton has expressed...
(Date:12/1/2009)...mber 1, 2009) The ADEAGies Foundation will honor ...ent Award at the Gies Awards celebration to be hel...unction with the 2010 ADEA Annual Session & Exhibi...ation, and Achievement recognize contributions to,...nitiatives. For a complete listing of Gies Award w...
Breaking Medicine News(10 mins):Health News:Swine Flu Waning, But Could Return 2Health News:Swine Flu Waning, But Could Return 3Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 2Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 3Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 4Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 5Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 6Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 7Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 8Health News:Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 9Health News:The Forsyth Institute receives the William J. Gies Award for outstanding achievement 2
...tin is being hailed as a new 'wonder drug' after i... cancer patients. New results of the trials show t...for the cancer, something that has never happened ...apse as compared to 127 cases in patients who were...
...h Organization survey reveals that currently more ... in India, with more and more number of cases bein.../have already been initiated in 36 hospitals acros...s and promote community participation, of four-day...
...m solving, visual spatial processing, memory, and ...lcoholism. Smoking is much more prevalent among al...ssible neurocognitive effects of cigarette smoking...am from the USA set out to determine whether smoki...
... Radiation oncologist and Craig Greven, Vitreoreti...ting patients with malignant melanoma of uvea with...a rare tumor that occurs in only six per one milli...were reported in American Society for Therapeutic ...
...e version of the prescription weight-loss medicati...l? 120 mg) was found to be safe, effective and tol...ew data presented today at the 2005 Annual Meeting... with a body mass index (BMI) of 25 to 28, demonst...
...nister Dr. Manmohan Singh and Union Health Ministe...eting on how India can face the problem of bird fl...nti-viral drugs are very less in India compared to...le flu attack. Dr. Anbumani said the Ministry plan...
Other Medicine News:Health News:Condom Vending Machines To Be Installed Across Indian States 2Health News:Radiation therapy effective against Eye cancer 2Health News:Weight-Loss Medication Evaluated By Nutrition Expert 2
Demineralized Cortical Powder, DGC20
...dance system offers the Zone, a graphical illustra...curacy has been established in nonclinical testing...alue. It is simple to set up, intutive and easily ...igation and comes with the touchpad for sterile fi...
Occipito-Cervical System
Cushing Rongeur
Medicine Products: